Poolbeg Pharma (POLB) Ord Shares
- Add to watchlist
- Create an alert
- This stock can be held in a
12.60p
13.00p
15.70p
£64.00 million
12.80p
12.60p
6.38p
n/a
0.35p (2.66%) Previous:
0.35p
875,875
n/a
30,000
Performance
Not available for this stock.
Fundamental data
Year ending: | 31/12/2023 | 31/12/2022 |
---|---|---|
Revenue (£m) | n/a | n/a |
Profit before tax (£m) | (4.50) | (4.78) |
Adjusted EPS (p): | (0.79) | (0.94) |
P/E ratio | n/a | n/a |
PEG | n/a | n/a |
EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: British pound
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
Poolbeg agrees 12-month option over potential Behcet's treatment
30 April 2024 16:43
-
Poolbeg Pharma to be granted US patent
20 March 2024 11:10
-
Director dealings: Poolbeg Pharma co-founder ups stake
19 February 2024 14:22
-
Annual Report & AGM Notice
9 May 2024 07:00
-
Significant POLB 001 Patent Granted in USA
1 May 2024 07:00
-
Appointment of Joint Broker
30 April 2024 07:02
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.